Cited by 186Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchAmino Acid Enzymes and Metabolism

Amyloid-β 1–42 Slows Clearance of Synaptically Released Glutamate by Mislocalizing Astrocytic GLT-1

Open access
Scimemi, Annalisa, Meabon, James S., Woltjer, Randall L., Sullivan, Jane M., Diamond, Jeffrey S., Cook, David G.·2013·The Journal of Neuroscience

Abstract

GLT-1, the major glutamate transporter in the adult brain, is abundantly expressed in astrocytic processes enveloping synapses. By limiting glutamate escape into the surrounding neuropil, GLT-1 preserves the spatial specificity of synaptic signaling. Here we show that the amyloid-β peptide Aβ 1–42 markedly prolongs the extracellular lifetime of synaptically released glutamate by reducing GLT-1 surface expression in mouse astrocytes and that this effect is prevented by the vitamin E derivative Trolox. These findings indicate that astrocytic glutamate transporter dysfunction may play an important role in the pathogenesis of Alzheimer's disease and suggest possible mechanisms by which several current treatment strategies could protect against the disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.5274-12.2013

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aβ42 impairs the function of GLT-1 and GLAST in hippocampal astrocytes.

    “while Aβ42 was shown to impair the function of the excitatory amino acid transporter (GLT-1) and the glutamate/aspartate transporter (GLAST) in hippocampal astrocytes [12].”

    From Emerging Role of miR-21-5p in Neuron–Glia Dysregulation and Exosome Transfer Using Multiple Models of Alzheimer’s Disease (2022) · cites this paper as [12]

    The Results (page not provided) show that Aβ1–42 reduced GLT-1 surface expression and slowed clearance of synaptically released glutamate. They do not show impaired GLAST function: GLAST surface expression was unchanged after treatment. The claim is supported for GLT-1, but not for GLAST. (LLM, conf=0.91)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Scimemi, A., Meabon, J. S., Woltjer, R. L., Sullivan, J. M., Diamond, J. S., & Cook, D. G.
Affiliations
  • National Institutes of Health (US)
  • VA Puget Sound Health Care System (US)
  • Oregon Health & Science University (US)
  • University of Washington (US)
Venue
The Journal of Neuroscience
Published
2013-03-20
Volume
33
Issue
12
Pages
5312-5318
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W1979889191
Cited by
185
References
28
Citations by year
2026: 8 · 2025: 16 · 2024: 23 · 2023: 9 · 2022: 22 · 2021: 15 · 2020: 18 · 2019: 12 · 2018: 11 · 2017: 19 · 2016: 7 · 2015: 13 · 2014: 11 · 2013: 1
FWCI
7.43
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (T32AG000258)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK017047)
  • National Institute of Neurological Disorders and Stroke (R01NS055804, ZIANS002986, Z01NS002986)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords
amyloid-beta 42, GLT-1, glutamate transporters, astrocytes, glutamate clearance, Alzheimer's disease, Trolox, vitamin E, extracellular glutamate
MeSH terms
Alzheimer Disease, Animals, Antioxidants, Astrocytes, Chromans, Drug Interactions, Extracellular Space, Female, Hippocampus, Male, Mice, Inbred C57BL, Models, Neurological, Neurons, Organ Culture Techniques, Peptide Fragments, Synapses, Amyloid beta-Peptides, Glutamic Acid, Excitatory Amino Acid Transporter 2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review